Rabbit anti Human BCRP (ATP-binding cassette sub-family G member 2)
| Code | Size | Price |
|---|
| EXA-X2731P | 100 ug | £316.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: Ig
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Application: Immunohistochemistry- Paraffin Embedded (IHC-P)
Shipping:
Ship at ambient temperature freeze upon arrival
Storage:
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles
Further Information
Applications Description:
Antibody can be used for immunohistochemistry at 5-10 ?g/ml on paraffin-embedded tissues. Optimal concentration should be evaluated by serial dilutions.
Background:
BCRP acts as a xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. May be involved in brain-to-blood efflux. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. When overexpressed, the transfected cells become resistant to mitoxantrone, daunorubicin and doxorubicin, display diminished intracellular accumulation of daunorubicin, and manifest an ATP-dependent increase in the efflux of rhodamine 123.
Caution:
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
Concentration:
See vial for concentration
Field of Interest:
Signal Transduction
Formulation:
Provided as solution in phosphate buffered saline with 0.08% sodium azide
Immunogen:
Synthetic peptide derived from human BCRP protein
Positive Control:
Highly expressed in placenta
Product Form:
Affinity Purified
Product Stability:
Products are stable for one year from purchase when stored properly
Purification Method:
Antigen Immunoaffinity Purification
Synonyms:
Breast cancer resistance protein; CDw338; Mitoxantrane resistance-associated protein; Placenta-specific ATP-binding cassette transporter
UniProt:
Q9UNQ0
References
1. Zhou, W., et al. 'The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.' Nat. Med. 2001, 7, 1028-1034.
2. Itoda, M., et al. ''Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan.' Drug Metab. Pharmacokinet. 2003, 18, 212-217.
3. Zamber, C.P., et al. 'Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.' Pharmacogenetics 2003, 13, 19-28.
2. Itoda, M., et al. ''Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan.' Drug Metab. Pharmacokinet. 2003, 18, 212-217.
3. Zamber, C.P., et al. 'Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.' Pharmacogenetics 2003, 13, 19-28.